|
IIL’s Karkapatla plant to be India’s largest producer of Animal Health Formulations
|
|
Our Bureau, Hyderabad
October 28 , 2015
|
|
|
The new plant of Indian Immunologicals Limited (IIL) at Karkapatla in
Hyderabad is set to become India’s largest producer of essential human
vaccines and animal health formulations in the country.
As part of its expansion plans, the company has invested about Rs.
250 crores to set up the state-of-art facility with a large
manufacturing capacity to meet the growing demand for vaccines in the
next 10 years.
“This unit at phase III of Genome Valley,
Karkapatla is IIL’s second manufacturing unit in Hyderabad. Spread
across 47 acres area, the plant will significantly expand IIL’s
manufacturing capabilities. The new facility has been established to
manufacture vaccines against infectious diseases of humans and animal
health formulations catering to domestic as well as international
market,” informed Dr. K. Anand kumar, deputy managing director, IIL.
IIL
had developed this facility considering the growing demand for the next
10 years for human vaccines and animal health formulations. Human
vaccine facility has been established to meet all WHO pre-qualification
standards. The first phase of human vaccine facility has the capacity to
produce 8 million doses of human rabies vaccine. The animal health
formulation facility is equipped to produce an estimated capacity of 300
million tablets, 100 million bolus, and 20 million vials of
injectables.
The plant is equipped with cutting-edge German
technology and has fully automated systems consisting of automated
granulation, compression lines which have the least possible human
intervention. This will become India’s largest facility for producing
animal health formulations. The facility currently equipped to
manufacture rabies vaccine for humans and produces new animal health
formulations for bovines, sheep and pets. The unit will provide direct
employment to 150 and indirect employment to 300 people.
“The
facility will strengthen IIL’s position in the industry and will
immensely increase our manufacturing capabilities. We are expecting this
plant to play a key role in manufacturing top quality vaccines with the
most recent German technology. We will strive to maintain our industry
leadership in providing the vaccines in the most affordable prices
without compromising on the quality,” added Dr. Kumar.
With the
new addition, IIL has 5 manufacturing facilities at various locations -
Ooty – anti rabies production unit; Rajkot, Gujarat – cattle feed unit;
Hyderabad, Gachibowli – biologicals unit; New Zealand – overseas serum
manufacturing unit. IIL currently employs around 1300 people.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|